{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:33:10Z","timestamp":1793158390840,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Canada First Nations and Inuit Branch, North region","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A remote arctic region of Canada predominantly populated by Inuit with the country\u2019s highest incidence of tuberculosis.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study was undertaken to describe the latent tuberculosis infection (LTBI) cascade of care and identify factors associated with non-initiation and non-completion of LTBI treatment. Data were extracted retrospectively from medical records for all patients with a tuberculin skin test (TST) implanted in Iqaluit, Nunavut between January 2012 and March 2016. Associations between demographic and clinical factors and both treatment non-initiation among and treatment non-completion were identified using log binomial regression models where convergence could be obtained and Poisson models with robust error variance where convergence was not obtained.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 2303 patients tested, 439 (19.1%) were diagnosed with LTBI. Treatment was offered to 328 patients, was initiated by 246 (75.0% of those offered) and was completed by 186 (75.6% of initiators). In multivariable analysis, older age (adjust risk ratio [aRR] 1.17 per 5-year increase, 95%CI:1.09\u20131.26) and undergoing TST due to employment screening (aRR 1.63, 95%CI:1.00\u20132.65, compared to following tuberculosis exposure) were associated with increased non-initiation of treatment. Older age (aRR 1.13, 95%CI: 1.03\u20131.17, per 5-year increase) was associated with increased non-completion of treatment.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A similar rate of treatment initiation and higher rate of treatment completion were found compared to previous North American studies. Interventions targeting older individuals and those identified via employment screening may be considered to help to address the largest losses in the cascade of care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-019-4557-3","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T17:02:35Z","timestamp":1572022955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The latent tuberculosis infection cascade of care in Iqaluit, Nunavut, 2012\u20132016"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-7413","authenticated-orcid":false,"given":"Christopher","family":"Pease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Zwerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeeta","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Demaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Van Dyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo G.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"issue":"3\/4","key":"4557_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.14745\/ccdr.v44i34a01","volume":"44","author":"J Vachon","year":"2018","unstructured":"Vachon J, Gallant V, Siu W. Tuberculosis in Canada, 2016. Can Commun Dis Rep. 2018;44(3\/4):75\u201381.","journal-title":"Can Commun Dis Rep"},{"key":"4557_CR2","unstructured":"Government of Canada SC. Census Profile, 2016 Census - Nunavut [Territory] and Iqaluit, City [Census subdivision], Nunavut [Internet]. 2017 [cited 2018 Jun 18]. Available from: \n                    http:\/\/www12.statcan.gc.ca\/census-recensement\/2016\/dp-pd\/prof\/details\/Page.cfm?Lang=E&Geo1=PR&Code1=62&Geo2=CSD&Code2=6204003&Data=Count&SearchText=Nunavut&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=62\n                    \n                  ."},{"key":"4557_CR3","unstructured":"Canada IS, Canada IS. Eliminating Tuberculosis across Inuit Nunangat by 2030; at least a 50% reduction by 2025 [Internet]. gcnws. 2018 [cited 2018 Jun 18]. Available from: \n                    https:\/\/www.canada.ca\/en\/indigenous-services-canada\/news\/2018\/03\/eliminating-tuberculosis-across-inuit-nunangat-by-2030-at-least-a-50-reduction-by-2025.html"},{"key":"4557_CR4","unstructured":"Inuit Tuberculosis Elimination Framework [Internet]. Inuit Tapiriit Kanatami; 2018. Available from: \n                    https:\/\/www.itk.ca\/wp-content\/uploads\/2018\/12\/FINAL-ElectronicEN-Inuit-TB-Elimination-Framework.pdf"},{"issue":"10","key":"4557_CR5","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1017\/S095026881100286X","volume":"140","author":"AN Hill","year":"2012","unstructured":"Hill AN, Becerra JE, Castro KG. Modelling tuberculosis trends in the USA. Epidemiol Infect. 2012 Oct;140(10):1862\u201372.","journal-title":"Epidemiol Infect"},{"key":"4557_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1146\/annurev-publhealth-031912-114431","volume":"34","author":"C Dye","year":"2013","unstructured":"Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health. 2013;34:271\u201386.","journal-title":"Annu Rev Public Health"},{"issue":"11","key":"4557_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016 Nov;16(11):1269\u201378.","journal-title":"Lancet Infect Dis"},{"issue":"3\/4","key":"4557_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.14745\/ccdr.v44i34a02","volume":"44","author":"M Patterson","year":"2018","unstructured":"Patterson M, Flinn S, Barker K. Addressing tuberculosis among Inuit in Canada. Can Commun Dis Rep. 2018;44(3\/4):82\u20135.","journal-title":"Can Commun Dis Rep"},{"issue":"7","key":"4557_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100975","volume":"9","author":"GG Alvarez","year":"2014","unstructured":"Alvarez GG, VanDyk DD, Aaron SD, Cameron DW, Davies N, Stephen N, et al. Taima (stop) TB: the impact of a multifaceted TB awareness and door-to-door campaign in residential areas of high risk for TB in Iqaluit. Nunavut PLoS ONE. 2014;9(7):e100975.","journal-title":"Nunavut PLoS ONE"},{"issue":"10","key":"4557_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.14745\/ccdr.v44i10a04","volume":"44","author":"R Dion","year":"2018","unstructured":"Dion R, Brisson M, Proulx J, Zoungrana H. Results of a population screening intervention for tuberculosis in a Nunavik village, Quebec, 2015\u20132016. Can Commun Dis Rep. 2018;44(10):257\u201363.","journal-title":"Can Commun Dis Rep"},{"key":"4557_CR11","unstructured":"Office of the Chief Medical Officer of Health. Reportable Communicable Diseases in Nunavut, 2007 to 2014 [Internet]. Government of Nunavut; 2016. Available from: \n                    https:\/\/www.gov.nu.ca\/sites\/default\/files\/reportable_communicable_diseases_in_nunavut_2007_to_2014.pdf"},{"key":"4557_CR12","unstructured":"Nunavut TB Control and Elimination Manual. Government of Nunavut.; 2010."},{"key":"4557_CR13","unstructured":"Canada PHA of. Canadian Tuberculosis Standards 7th Edition: 2014 [Internet]. Long R, editor. 2014 [cited 2017 Nov 19]. Available from: \n                    https:\/\/www.canada.ca\/en\/public-health\/services\/infectious-diseases\/canadian-tuberculosis-standards-7th-edition.html"},{"issue":"11","key":"4557_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111986","volume":"9","author":"GG Alvarez","year":"2014","unstructured":"Alvarez GG, Van Dyk DD, Davies N, Aaron SD, Cameron DW, Desjardins M, et al. The feasibility of the interferon gamma release assay and predictors of discordance with the tuberculin skin test for the diagnosis of latent tuberculosis infection in a remote aboriginal community. PLoS One. 2014;9(11):e111986.","journal-title":"PLoS One"},{"issue":"1","key":"4557_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","volume":"17","author":"C Pease","year":"2017","unstructured":"Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017 Apr 11;17(1):265.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"4557_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004 Apr 1;159(7):702\u20136.","journal-title":"Am J Epidemiol"},{"issue":"12 Suppl 3","key":"4557_CR17","first-page":"S384","volume":"7","author":"J Jereb","year":"2003","unstructured":"Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis. 2003 Dec;7(12 Suppl 3):S384\u201390.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"4557_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1378\/chest.09-0394","volume":"137","author":"CR Horsburgh","year":"2010","unstructured":"Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010 Feb;137(2):401\u20139.","journal-title":"Chest."},{"issue":"3","key":"4557_CR19","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.17269\/cjph.104.3643","volume":"104","author":"P Rivest","year":"2013","unstructured":"Rivest P, Street M-C, Allard R. Completion rates of treatment for latent tuberculosis infection in Quebec, Canada from 2006 to 2010. Can J Public Health. 2013 May 14;104(3):e235\u20139.","journal-title":"Can J Public Health"},{"issue":"11","key":"4557_CR20","first-page":"1374","volume":"14","author":"H Kunst","year":"2010","unstructured":"Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis. 2010 Nov;14(11):1374\u201381.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"8","key":"4557_CR21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006 Oct 15;174(8):935\u201352.","journal-title":"Am J Respir Crit Care Med"},{"key":"4557_CR22","first-page":"1","volume":"19","author":"I Sutherland","year":"1976","unstructured":"Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res. 1976;19:1\u201363.","journal-title":"Adv Tuberc Res"},{"issue":"23","key":"4557_CR23","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8;365(23):2155\u201366.","journal-title":"N Engl J Med"},{"issue":"6","key":"4557_CR24","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","volume":"46","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015 Dec;46(6):1563\u201376.","journal-title":"Eur Respir J"},{"issue":"2","key":"4557_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cid\/ciw778","volume":"64","author":"DM Lewinsohn","year":"2017","unstructured":"Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):111\u20135.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4557_CR26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/cid\/cix745","volume":"66","author":"L Mu\u00f1oz","year":"2018","unstructured":"Mu\u00f1oz L, Santin M, Alcaide F, Ru\u00edz-Serrano MJ, Gij\u00f3n P, Berm\u00fadez E, et al. QuantiFERON-TB gold in-tube as a confirmatory test for tuberculin skin test in tuberculosis contact tracing: a noninferiority clinical trial. Clin Infect Dis. 2018 Jan 18;66(3):396\u2013403.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4557_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1164\/ajrccm.159.1.9801120","volume":"159","author":"D Menzies","year":"1999","unstructured":"Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med. 1999 Jan;159(1):15\u201321.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4557-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4557-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4557-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T23:07:43Z","timestamp":1603408063000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4557-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4557"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4557-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"18 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Nunavut Research Institute Research license was obtained for the study. Approval of the Ottawa Health Science Network Research Ethics Board was also obtained for the collection and analysis of the data. Permission to access data was provided by Iqaluit Public Health.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AZ is an editorial board member for BMC Infectious Diseases. The authors declare that they have no other competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"890"}}